BCYC
Price
$3.46
Change
-$0.14 (-3.89%)
Updated
Oct 16 closing price
Capitalization
259.67M
12 days until earnings call
Intraday BUY SELL Signals
MGX
Price
$0.78
Change
-$0.07 (-8.24%)
Updated
Oct 16 closing price
Capitalization
43.07M
32 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BCYC vs MGX

BCYC vs MGX Comparison Chart in %
View a ticker or compare two or three
VS
BCYC vs. MGX commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and MGX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for BCYC with price predictions
Oct 16, 2026

BCYC sees MACD Histogram just turned negative

BCYC saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In 44 of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

BCYC moved below its 50-day moving average on October 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for BCYC crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCYC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

BCYC broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for BCYC entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BCYC's RSI Indicator exited the oversold zone, 41 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on BCYC as a result. In 66 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

Following a +4.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCYC advanced for three days, in 190 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.509) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (4.136) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 77 (best 1 - 100 worst), indicating slightly worse than average price growth. BCYC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCYC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for MGX with price predictions
Oct 16, 2026

Momentum Indicator for MGX turns negative, indicating new downward trend

MGX saw its Momentum Indicator move below the 0 level on September 15, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator turned negative. In 35 of the 39 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for MGX turned negative on September 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 21 similar instances when the indicator turned negative. In 16 of the 21 cases the stock turned lower in the days that followed. This puts the odds of success at 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for MGX entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 110 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 7 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.383) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
BCYC: Fundamental Ratings
BCYC
OUTLOOK RATING
1..100
76
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
77
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
BCYCMGX
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
69%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
77%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 1 day ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
73%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
84%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (BCYC: $3.46 vs. MGX: $0.78)
Brand notoriety: BCYC and MGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 109% vs. MGX: 89%
Market capitalization -- BCYC: $259.67M vs. MGX: $43.07M
BCYC [@Biotechnology] is valued at $259.67M. MGX’s [@Biotechnology] market capitalization is $43.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green while MGX’s FA Score has 1 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • MGX’s FA Score: 1 green, 4 red.
According to our system of comparison, both BCYC and MGX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 4 TA indicator(s) are bullish while MGX’s TA Score has 4 bullish TA indicator(s).

  • BCYC’s TA Score: 4 bullish, 6 bearish.
  • MGX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MGX is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а -11.05% price change this week, while MGX (@Biotechnology) price change was -21.60% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.78%. For the same industry, the average monthly price growth was -18.33%, and the average quarterly price growth was -21.56%.

Reported Earning Dates

BCYC is expected to report earnings on Oct 29, 2026.

MGX is expected to report earnings on Nov 18, 2026.

Industries' Descriptions

@Biotechnology (-10.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
BCYC
Daily Signal:
Gain/Loss:
MGX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ACP4.440.09
+2.07%
abrdn Income Credit Strategies Fund
TBLU50.21N/A
N/A
Tortoise Global Water ETF (TBLU)
STAX24.92N/A
N/A
Nomura Tax-Free USA Short Term ETF (STAX)
CNYA31.80-0.37
-1.15%
iShares MSCI China A ETF (CNYA)
ICVT105.08-2.38
-2.21%
iShares Convertible Bond ETF (ICVT)

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with VYGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then VYGR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
-7.24%
VYGR - MGX
48%
Loosely correlated
-7.77%
EDIT - MGX
48%
Loosely correlated
-3.69%
SANA - MGX
43%
Loosely correlated
-8.28%
BCYC - MGX
42%
Loosely correlated
-3.89%
RXRX - MGX
42%
Loosely correlated
-16.71%
More